Incyte Reports 2019 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
Go back to Incyte Reports 2019 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
October 30, 2019 8:03 AM EDT
Mizuho Securities analyst Mara Goldstein raised the price target on Incyte (NASDAQ: INCY) to $98.00 (from $95.00) while maintaining a Buy rating.
The analyst commented, "We continue to like INCY based on the combination of cash flow generated by JAKAFI and opportunities from potential... More
October 29, 2019 7:12 AM EDT
Incyte (NASDAQ: INCY) reported Q3 EPS of $0.82, $0.17 better than the analyst estimate of $0.65. Revenue for the quarter came in at $551.58 million versus the consensus estimate of $534.88 million.
Total product and royalty revenues of $534 million (+24% vs. Q3 2018) and Jakafi® (ruxolitinib) revenues of $433 million (+25% vs. Q3 2018) for the quarter ended September 30, 2019;...
More
